Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
UBS
Healthtrust
Mallinckrodt
Daiichi Sankyo
Baxter
AstraZeneca
Harvard Business School
US Army
Johnson and Johnson

Generated: February 20, 2018

DrugPatentWatch Database Preview

VIZAMYL Drug Profile

« Back to Dashboard

When do Vizamyl patents expire, and what generic alternatives are available?

Vizamyl is a drug marketed by Ge Healthcare and is included in one NDA. There are five patents protecting this drug.

This drug has seventy-six patent family members in twenty-three countries.

The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this compound. Additional details are available on the flutemetamol f-18 profile page.
Summary for VIZAMYL
International Patents:76
US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 1
Clinical Trials: 3
Patent Applications: 14
Drug Prices:see details
DailyMed Link:VIZAMYL at DailyMed
Drug patent expirations by year for VIZAMYL
Pharmacology for VIZAMYL

US Patents and Regulatory Information for VIZAMYL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for VIZAMYL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,854,920 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Try a Free Trial
9,134,328 Methods of using benzothiazole derivative compounds and compositions ➤ Try a Free Trial
9,808,541 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Try a Free Trial
9,833,458 Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Try a Free Trial
8,404,213 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Try a Free Trial
8,911,707 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for VIZAMYL

Supplementary Protection Certificates for VIZAMYL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0006 France ➤ Try a Free Trial PRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
00723 Netherlands ➤ Try a Free Trial PRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
90009-5 Sweden ➤ Try a Free Trial PRODUCT NAME: FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140826
2015 00008 Denmark ➤ Try a Free Trial PRODUCT NAME: RADIOAKTIVE ISOTOPER AF FLUTEMETAMOL, SAERLIGT FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140822
00724 Netherlands ➤ Try a Free Trial PRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
15/005 Ireland ➤ Try a Free Trial PRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
634 Luxembourg ➤ Try a Free Trial PRODUCT NAME: FLUTEMETAMOL (18F) ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VIZAMYL). FIRST REGISTRATION: 20140826
2015000016 Germany ➤ Try a Free Trial PRODUCT NAME: FLUTEMETAMOL (18F) ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ, HYDRAT ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/14/941 20140822
2015 Austria ➤ Try a Free Trial PRODUCT NAME: (18F) - FLUTEMETAMOL; REGISTRATION NO/DATE: EU/1/14/941 (MITTEILUNG) 20140826
0150004 00139 Estonia ➤ Try a Free Trial PRODUCT NAME: FLUTEMETAMOOL (18F);REG NO/DATE: EU/1/14/941 26.08.2014
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Colorcon
Argus Health
Queensland Health
US Army
Harvard Business School
QuintilesIMS
Daiichi Sankyo
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot